1. Introduction {#sec1-1}
===============

Clozapine (CLZ) is an atypical antipsychotic used in treating schizophrenia. It is generally accepted that CLZ is an effective medication for the treatment of schizophrenia. CLZ has no significant extrapyramidal reactions. It not only has effect on positive/negative symptoms, impulsive aggressive behavior, but also improves cognitive function in those with schizophrenia. The efficacy of CLZ has been shown to be about 30 to 60% for those with refractory schizophrenia.^\[[@ref1],\ [@ref2]\]^

CLZ is absorbed quickly in the body, and if its serum concentration exceeds a certain range, significant side effects (leukopenia, fewer granulocytes) will occur. The potentially permanent movement disorder tardive dyskinesia occurs in about 5% schizophrenia patients with CLZ. Its mechanism of action is not entirely clear. Therefore, therapeutic drug monitoring is necessary to monitor serum CLZ concentration and to reduce side effects.^\[[@ref1]\]^

CLZ is often combined with other psychotropic drugs according to the patient's clinical condition, and therefore CLZ sometimes has drug--drug interactions with other psychotropic drugs in the treatment of comorbid physical and mental illnesses. Most pharmacokinetic interactions with CLZ and other psychotropic drugs occur at the metabolic level and usually involve changes in the activity of the major drug-metabolizing enzymes involved in their biotransformation.

Clonazepam (CLNAZ), as a tranquilizer of the benzodiazepine class and a broad-spectrum antiseizure drug, also can be used to treat sleep disorders, the movement disorder known as akathisia, reduce anxiety, and improve sleep quality.^\[[@ref3]\]^ CLNAZ binds to GABAA receptors and increases the effect of the neurotransmitter GABA.

Depending on the circumstances, doctors sometimes prescribe CLZ alongt with CLNAZ. However research into whether co-medication with CLNAZ has an impact on the serum concentration of CLZ and its major metabolite norclozapine (N-CLZ) in schizophrenia is relatively scarce. Our retrospective survey is to investigate the effects of co-medication with CLNAZ and other factors on the serum levels of CLZ, andN-CLZ concentrations in 341 patients with schizophrenia. We aim to provide further evidence for the improvement of therapeutic drug monitoring and individualizing of dosages of CLZ for individuals with schizophrenia who are also on CLNAZ.^\[[@ref4]\]^

2. Methods {#sec1-2}
==========

2.1 Participants {#sec2-1}
----------------

A retrospective survey of serum CLZ and N-CLZ concentrations of in patients with schizophrenia was conducted at Shanghai Mental Health Centre, Shanghai, China from December 2007 to December 2010. This study was approved by the Institutional Ethics Committee of the Shanghai Mental Health Center (IORG Number: IORG0002202, FWA Number: FWA00003065). The Institutional Ethics Committee, Shanghai Mental Health Center also approved the consent procedure. As shown in [figure 1](#fig001){ref-type="fig"}, 387 patients were initially chosen and 341 were included in the final analysis.

There were in total 341 patients (217 male, 124 female; mean(sd) age of 45.4(10.8) years). We analyzed patients' CLZ dosage, serum CLZ and N-CLZ concentrations and CLNAZ co-medication. We determined patients' serum concentrations of CLZ and N-CLZ 3 times in the previous 3 months. The mean CLZ dose for 341 patients was 254.2 (189.1-354.2) mg/ d. Within this group, 94 of the patients went through monotherapy using CLZ (CLZ group:70 males, 24 females; mean (sd) age, 42.2(12.0) years; mean CLZ dose 280.7 (216.1-396.9) mg/d).The other 247 patients were treated with CLNAZ in addition to CLZ (comedication CLNAZ group: 147 males, 100 females; mean (sd) age, 46.6(10.1) years; mean CLZ dose, 250.0(177.5-345.0) mg/d). See [table 1](#table001){ref-type="table"} for demographic information. In this retrospective survey, all data (serum CLZ and N-CLZ concentrations, demographic information) were collected from medical archives.

The inpatients who had been taking CLZ for at least two weeks had serum extracted from the cubital vein 5ml from 6-7 pm (11-12 hours after the last medication). Serum samples were analyzed by high performance liquid chromatography (HPLC) to determine serum concentration of CLZ and N-CLZ, its metabolite.

2.2 Sample process {#sec2-2}
------------------

A solution system composed of 0.5mL serum, 0.1mL alcohol of 2 moL/L NaOH, 15μl alcohol of 10 ng/μL diazepam (internal standard) and 3mL ethylether was used. By vortexing for 1 min, the organic layer was separated into the tapered tube, and was evaporated at 60°C. The residue was dissolved into a 100μL flow. Agilent 1200 HPLC analyzer was used in this study. Conditions of chromatography: Chromatographic column was the C18 column. The mobile phase was composed of methanol: glacial acetic acid : tetramethylethylenediamine : water (2800:10:9:1440). The detection wavelength was 254nm. CLZ, N-CLZ and diazepam (internal standard) were purchased from Sigma Company.

2.3 Statistics {#sec2-3}
--------------

Data was analyzed by stepwise regression using SPSS 21.0 software. Independent variables included the following: Gender(X~1~)(male=0, female=1), Age(X~2~), CLZ dosage(X~3~), Co-medication dosage of CLNAZ (X~4~) (No=0, Yes=1). Normally distributed data (e.g. age, comedication CLNAZ dosage) was expressed as mean (sd); non-normally distributed data (e.g. CLZ dosages, CLZ serum concentration, N-CLZ serum concentration) was expressed as the median (IQR25-IQR75). The t-test was used for comparing 2 groups' normally distributed data and Mann-Whitney rank sum test was used for comparing the 2 groups non-normally distributed data. Statistical significance level was set at p\<0.05.

3. Results {#sec1-3}
==========

3.1 Demographic Data {#sec2-4}
--------------------

Of the 341 patients included for analysis in this study, 27.6% were taking CLZ (n=94:M70 and F24; mean (sd) age:42.2(12.0) years; median CLZ dosage: 280.7(216.1-396.9) mg/d). Patients who were taking CLNAZ in addition to CLZ accounted for 72.4% of all patients in this analysis (n=247:M147 and F100; mean (sd) age: 46.6(10.1) years; median CLZ dosage: 250.0(177.5-345.0) mg/d). See [table 1](#table001){ref-type="table"}.

3.2 CLZ group and CLZ plus CLNAZ group {#sec2-5}
--------------------------------------

The mean (sd) age of the CLZ plus CLNAZ group (43.5\[11.1\] years) was significantly higher than the CLZ group's (42.1\[12.1\] years) (p=0.002). The median CLZ dosage (250.0 (177.5-345.0) mg/d) in the CLZ plus CLNAZ group was significantly lower than that of the CLZ group (280.7(216.1-396.9) mg/d) *(p=* 0.023). Median CLZ and N-CLZ serum concentrations in the CLZ plus CLNAZ group (368.5(233.3-530.8) ng/ml,177.4(103.6-240.1) ng/ml) were significanty lower than in the CLZ group (431.5(285.7-633.1) ng/ml, 206.1(110.4-300.9) ng/ml)(p=0.013; p=0.013) respectively. Median CLZ + N-CLZ serum concentrations in the CLZ plus CLNAZ group (528.0(335.2-773.0) ng/ml) were significantly lower than those of the CLZ group (641.4(417.8-951.6) ng/ml)(*P =* 0.010), as shown in [Table 1](#table001){ref-type="table"}.

3.3 Differences by gender in the CLZ plus CLNAZ group {#sec2-6}
-----------------------------------------------------

The mean (sd) age of those in the CLZ plus CLNAZ group (48.7\[9.7\] years) was significantly higher than that of the CLZ only group (42.3\[10.7\] years) (p=0.005). Median CLZ and N-CLZ serum concentrations of females in the CLZ plus CLNAZ group (381.2\[230.1-549.4\] ng/ ml,172.7\[103.0-238.8\] ng/ml) were significantly lower than those of the CLZ group (569.5\[340.6-725.6\] ng/ ml, 235.0 \[174.7-344.0\] ng/ml)(*p=*0.018; *p=*0.013) respectively. CLZ + N-CLZ serum concentrations of females in the CLZ plus CLNAZ group (545.8\[350.0-793.2\] ng/ml) was significantly lower than that of the CLZ group (817.9\[534.4-1039.1\] ng/ml)(p=0.010), as shown in [Table 1](#table001){ref-type="table"}.

3.4 Stepwise Regression Analyses {#sec2-7}
--------------------------------

SPSS 21.0 was used to perform stepwise regression analysis. We gradually removed or selected factors affecting the serum concentration of CLZ and N-CLZ. The results showed: Gender (X1), CLZ dosage (X3) and Co-medication of CLNAZ with CLZ (X4), these three factors were significantly associated with CLZ serum concentration (p=0.009, p\<0.001, p=0.010). Age (X2) was not significantly associated with CLZ serum concentration (p=0.625). CLZ serum concentration was set as the dependent variable (Y) and the regression equation was: y=366.25+71.01 X1+0.39 X3-74.51 X4. Therefore, the CLZ serum concentration (Y) was negatively correlated with co-medication of CLNAZ with CLZ (X4), and positively correlated with gender (X1) and CLZ dosage (X3). See [table 2](#table002){ref-type="table"}.

CLZ dosage (X3) and co-medication with CLNAZ (X4) were two factors that were significantly associated with N-CLZ serum concentration (p\<0.001, p=0.020). Gender (X1) and age (X2) were not significantly associated with N-CLZ serum concentration (p=0.196, p=0.894). N-CLZ serum concentration was set as the dependent variable (Y) and the regression equation was: Y=156.85 + 0.20 X3-35.43 X4. That means that co-medication with CLNAZ is associated with a lower N-CLZ serum concentration, while a higher CLZ dosage is associated with a higher N-CLZ serum concentration (see [table 3](#table003){ref-type="table"}).

4. Discussion {#sec1-4}
=============

4.1 Main findings {#sec2-8}
-----------------

In this study, we retrospectively analyzed the serum CLZ and N-CLZ concentrations, co-medication with CLNAZ, and demographic data for 341 Chinese patients with schizophrenia. We further explored the effects of CLNAZ co-medication and other related factors on serum CLZ, N -CLZ concentration in Chinese patients with schizophrenia. In our retrospectively study, serum CLZ, N-CLZ and CLZ + N-CLZ concentrations in the CLZ plus co-medication with CLNAZ group were both statistically significant lower than that of the CLZ group respectively. The regression analysis results showed that serum CLZ and N-CLZ concentration were significantly different for those patients who were being co-medicated with CLNAZ and that co-medication with CLNAZ is negatively related to serum CLZ and N-CLZ concentration.

About 23% of antipsychotic-treated (more than 1 year) schizophrenic patients have Tardive Dyskinesia (TD) symptoms. TD is an involuntary movement disorder characterized by complex repetitive neck, buccolingual and sometimes generalized stereotypic hyperkinetic features. Moreover, TD may even be life-threatening owing to such complications as dysphagia, respiratory disturbances, and renal failure from dehydration or rhabdomyolysis caused by muscle breakdown from increased motor activity. The mechanism of TD is still unclear,^\[[@ref5]\]^therefore this condition is difficult to treat and there is no single drug considered 100% effective in rapidly reducing TD symptoms. According to the patient's condition, CLZ and CLNAZ are often concomitant medications, which means both antipsychotic drugs CLZ and CLNAZ with advance-rapid onset, effective sedation and long half-life will have effect. Kimiagar concurrently used three drugs (CLZ, CLNAZ, tetrabenazine) to treat six severe TD patients with psychotic disorders (5 had schizophrenia and 1 had bipolar disorder with psychotic features). After treatment, there were fewer incidences of patients having convulsions. Four patients' symptoms markedly improved after 1 week, and all six patients' TD symptoms disappeared completely after 4 weeks.^\[[@ref6],[@ref7]\]^

There are several possible mechanisms for comedication of CLZ and CLNAZ improving the symptoms of TD for those with schizophrenia. Patients whose NE activity is increased via the atypical antipsychotic CLZ inhibiting norepinephrine (NE) systems or patients whose presynaptic membrane NE receptor activity is increased have a tendency to have TD. CLNAZ belongs to the benzodiazepine class of drugs. Benzodiazepine receptors with gamma aminobutyric acid (GABA) receptors constitute GABA-benzodiazepine-Cl^-^ channel complex, and CLNAZ strengthens GABA energy nerve conduction in the GABA-benzodiazepine-Cl^-^ channel complex in TD patients or patients have a tendency to have TD. Therefore, in a way, co-medication with CLNAZ increases serum CLZ concentration.^\[[@ref8],[@ref9]\]^

Excessive serum CLZ concentration may trigger a series of toxic, even life-threatening physical reactions. Clinicians will lower CLZ dosages to maintain serum CLZ and N-CLZ concentration within a safe range that avoids toxicity side effects.^\[[@ref8],[@ref9]\]^ This may explain why both CLZ dosage and serum CLZ, N-CLZ, CLZ+N-CLZ concentrations in co-medication with CLNAZ group were significantly lower than those of the CLZ group. Meanwhile, this may at least partly be the reason that co-medication with CLNAZ was negatively correlated with serum concentration of CLZ and N-CLZ. Another result shows that CLZ dose was significantly and positively correlated with CLZ and N-CLZ serum concentration in both the CLZ only group and co-medication with CLNAZ group. This result is consistent with a study by Chang and colleagues. CLZ serum concentration in CLZ group, 431.5(285.7-633.1) ng/ml, was just within the effective blood concentration range (300-600) ng/ml. The serum CLZ concentration in the co-medication with CLNAZ group is 368.5(233.3-530.8) ng/ml, was slightly lower that the effective blood concentration range. This showed that the patients included in this study had relatively safe and effective use of CLZ.^\[[@ref9],[@ref10]\]^

Female CLZ serum concentration was relatively higher in this study, which is consistent with Lin's study.^\[[@ref11]\]^ The main metabolic pathway of CLZ in vivo is demethylation. CLZ is catalyzed into norclozapine (N-CLZ) in the liver by CYP1A2 and other enzymes. CYP1A2 activity directly affects serum concentration of CLZ and N-CLZ, and indirectly affects the improvement of psychopathological symptoms. Gender and other factors (e.g. smoking) may have lead to the female patients' serum CLZ concentration being higher than those seen among the male patients in this study. There can be up to a 70 times greater difference in CYP1A2 between individuals which may partly account for the differences in serum CLZ concentration (max difference was 3.4 higher) among participants in this study.

An interesting result is all the serum CLZ, N-CLZ, CLZ+N-CLZ concentrations of females in the comedication with CLNAZ group were significantly lower than those of the CLZ group while CLZ dosage was not significantly different. There is a possibility that CLZ metabolism was improved by co-medication with CLNAZ to a greater extent in female patients than male patients. However this question requires further investigation.

4.2 Limitations {#sec2-9}
---------------

In this retrospective study, the co-medication group and control group had different sample sizes, and the factors for state, type, course and complications of schizophrenia were not controlled. Given these limitations, the conclusions need to be further verified. In the future, prospective experiments should be designed with this consideration in mind. The sample size and the state, type, course and complications of schizophrenia in groups need to be controlled. Future studies should also have scales to evaluate patients' outcomes.

4.3 Implications {#sec2-10}
----------------

CLZ co-medicated with CLNAZ is an effective treatment method for patients with schizophrenia. Therapeutic drug monitoring of CLZ in patients with schizophrenia is very important. CLZ doses should be adjusted in a timely manner to achieve the best therapeutic effect when comedication with CLNAZ is being considered. ^\[[@ref5],[@ref9],[@ref12],[@ref13]\]^
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###### 

Demographic information and Serum Concentration of CLZ, N-CLZ

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                            CLZ group             Gender                CLZ plus CLNAZ group   Gender                statistic             *p*-value                           
  ---------------------------------------------------- --------------------- --------------------- ---------------------- --------------------- --------------------- --------------------- ------------- ------------------------------------------------
  N                                                    94                    70                    24                     247                   147                   100                                 

  mean (sd) age (years)                                42.2(12.0)            42.2(12.5)            42.3(10.7)             46.6(10.1)            45.2(10.1)            48.7(9.7)             t^a^=-3.16\   ^[a](#table1-tfn1){ref-type="table-fn"}^0.002\
                                                                                                                                                                                            t^b^=-1.77\   ^[b](#table1-tfn2){ref-type="table-fn"}^0.079\
                                                                                                                                                                                            t^c^=-2.84    ^[c](#table1-tfn3){ref-type="table-fn"}^0.005

  median (IQR) CLZ dosage (mg/d)                       280.7 (216.1-396.9)   286.9 (225.0-400.0)   269.4 (200.0-364.6)    250.0 (177.5-345.0)   266.0 (195.0-370.0)   235.9 (154.1-300.0)   Z^a^=-2.27\   ^[a](#table1-tfn1){ref-type="table-fn"}^0.023\
                                                                                                                                                                                            Z^b^=-1.14\   ^[b](#table1-tfn2){ref-type="table-fn"}^0.255\
                                                                                                                                                                                            Z^c^=-1.64    ^[c](#table1-tfn3){ref-type="table-fn"}^0.102

  median (IQR) CLZ serum concentration (ng/ml)         431.5 (285.7-633.1)   410.5 (248.0-562.9)   569.5 (340.6-725.6)    368.5 (233.3-530.8)   350.5 (233.3-496.8)   381.2 (230.1-549.4)   Z^a^=-2.49\   ^[a](#table1-tfn1){ref-type="table-fn"}^0.013\
                                                                                                                                                                                            Z^b^=-1.71\   ^[b](#table1-tfn2){ref-type="table-fn"}^0.087\
                                                                                                                                                                                            Z^c^=-2.36    ^[c](#table1-tfn3){ref-type="table-fn"}^0.018

  median(IQR) N-CLZ serum concentration (ng/ml)        206.1 (110.4-300.9)   199.5 (103.3-284.8)   235.0 (174.7-344.0)    177.4 (103.6-240.1)   171.4 (98.9-245.2)    172.7 (103.0-238.8)   Z^a^=-2.48\   ^[a](#table1-tfn1){ref-type="table-fn"}^0.013\
                                                                                                                                                                                            Z^b^=-1.46\   ^[b](#table1-tfn2){ref-type="table-fn"}^0.143\
                                                                                                                                                                                            Z^c^=-2.49    ^[c](#table1-tfn3){ref-type="table-fn"}^0.013

  median(IQR) CLZ+ N-CLZ serum concentration (ng/ml)   641.4 (417.8-951.6)   588.6 (406.6-884.7)   817.9 (534.4-1039.1)   528.0 (335.2-773.0)   504.8 (332.0-761.6)   545.8 (350.0-793.2)   Z^a^=-2.58\   ^[a](#table1-tfn1){ref-type="table-fn"}^0.010\
                                                                                                                                                                                            Z^b^=-1.70\   ^[b](#table1-tfn2){ref-type="table-fn"}^0.089\
                                                                                                                                                                                            Z^c^=-2.44    ^[c](#table1-tfn3){ref-type="table-fn"}^0.015

  mean(sd) CLNAZ dosage (mg/d)                                                                                            2.8(1.3)              2.9(1.3)              2.7(1.2)                            
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

t^a^, t^b^, t^c^-value from T test

Z^a^, Z^b^, Z^c^-value from Mann-Whitney rank test

^a^ Comedication CLNAZ group VS CLZ group

^b^ male in Comedication CLNAZ group VS male in CLZ group

^c^ female in Comedication CLNAZ group VS female in CLZ group

###### 

Stepwise regression analysis^[a](#table2-tfn1){ref-type="table-fn"}^ for factors related to CLZ serum concentration in patients with schizophrenia (n=341)

  Independent Variables      Unstandardized Coefficients (B)   Unstandardized Coefficients (Std. Error)   Standardized Coefficients (Beta)   *t*-value   p-value
  -------------------------- --------------------------------- ------------------------------------------ ---------------------------------- ----------- ---------
  Constant                   366.25                            63.10                                                                         5.80        \<0.001
  Age                        -0.58                             1.19                                       -0.03                              -0.49       0.625
  Gender                     71.01                             26.88                                      0.14                               2.64        0.009
  CLZ dosage                 0.39                              0.09                                       0.23                               4.35        \<0.001
  Co-medication with CLNAZ   -74.51                            28.92                                      -0.14                              -2.58       0.010

^a^Adjusted R Squares of this equation is 0.075, F= 7.85, p\<0.001

###### 

Stepwise regression analysis^[a](#table3-tfn1){ref-type="table-fn"}^ for factors related to N-CLZ serum concentration in patients with schizophrenia (n=341)

  Independent Variables      Unstandardized Coefficients (B)   Unstandardized Coefficients (Std. Error)   Standardized Coefficients (Beta)   *t*-value   *p*-value
  -------------------------- --------------------------------- ------------------------------------------ ---------------------------------- ----------- -----------
  Constant                   156.85                            33.09                                                                         4.74        \<0.001
  Age                        0.08                              0.63                                       0.01                               0.13        0.894
  Gender                     18.28                             14.10                                      0.07                               1.30        0.196
  CLZ dosage                 0.20                              0.05                                       0.23                               4.35        \<0.001
  Co-medication with CLNAZ   -35.43                            15.17                                      -0.13                              -2.34       0.020

^a^Adjusted R Squares of this equation is 0.062, F=6.64, p\<0.001
